News Agency
The Times

Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH

  • Written by PR Newswire

SHANGHAI, Jan. 19, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today reported positive top-line results from the Phase 2a RISE clinical trial of HPG1860, a next generation non-bile acid, liver selective farnesoid X...

Read more: Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion